



# HyGleaCare® Receives First Patent from USPTO

*HyGleaCare's patent covers a system for treatment and/or diagnosis utilizing a colon irrigation system together with novel analytical features*

AUSTIN, TX, UNITED STATES, September 28, 2017 /EINPresswire.com/ -- HygieaCare Inc. announced today that the USPTO has notified the Company that on October 3rd its US Patent application will be issued as USP Number 9775865. The patent relates to systems for characterization of the contents of the large intestine and treatment of conditions of the large intestine.

The patent covers a system for treatment and/or diagnosis of a condition in a patient's large intestine utilizing a colon irrigation system and an analysis module configured in a certain manner, together with additional novel analytical features including an acoustic array to listen to the colon for noise mapping and potential identification of conditions, a camera to enable visual diagnosis based on excretions, and therapeutic infusion of donor stool, autologous stool or other therapeutic compounds based on the analysis of excreted stool. Also covered under this patent is a stool bank for large intestine contents' samples from patients performing colon irrigation, associated with derived microbiome characteristics of these samples.

Since inception in 2015 HyGleaCare has established [HyGleaCare Centers](#) providing bowel preparation without all the associated side effects of the current preparation and with consistently high cleanliness rates. More than 5,000 patients have performed the prep with 97% of them having an adequately clean colon, with ZERO severe adverse events and excellent patient and physician feedback. This technology is now being increasingly implemented in a growing number of leading GI groups in the US. With increasing adoption, HyGleaCare will establish a Platform upon which additional patented offerings can be stacked, enhancing the value of each Center while creating higher barriers of entry.

"This patent allows HyGleaCare to potentially be a unique player in the field of microbiome research aimed at providing new diagnostic and therapeutic paths for diseases in the population," said Gavriel Meron, Chairman and CEO of HyGleaCare. "This paves the path for HyGleaCare to consistently gather stool samples for microbiome analysis from regions in the GI tract that currently cannot readily be sampled."

For more information about HyGleaCare® please go to: <http://www.hygieacare.com>

About [HyGleaCare, Inc.](#)

Chairman and CEO Gavriel (Gabi) Meron - the founder and former CEO of Given Imaging, the Company that successfully brought the PillCam to the world - partnered with Texas-based Lifestream Purification Systems to form HyGleaCare, Inc. to bring the HyGleaCare FDA-cleared Prep System and procedure exclusively to the GI world.

The goal of HyGleaCare ([www.hygieacare.com](http://www.hygieacare.com)) is to provide unique services and solutions to gastroenterologists to deliver better GI outcomes for their patients and their practice through

HyGleaCare Centers to be established in the US and throughout the world.

Michal Gorodish Vice President Marketing  
hygieacare inc.  
(470) 819-8351  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.